Tarafenacin

"目录号: HY-14825A

GPCR/G ProteinNeuronal Signaling-

Tarafenacin(SVT-40776)D型酒石酸盐是高亲和性M3毒蕈碱受体选择性拮抗剂，Ki为0.19 nM，比对M2受体的亲和性高200倍。

mAChR

相关产品

Pilocarpine Hydrochloride-Scopolamine hydrobromide-Carbamoylcholine chloride-Methacholine chloride-Xanomeline oxalate-Atropine sulfate monohydrate-Bethanechol chloride-Imidafenacin-Aclidinium Bromide-Benztropine mesylate-Biperiden Hydrochloride-Diphenmanil methylsulfate-TBPB-Umeclidinium bromide-Arecoline hydrobromide-

生物活性

Description

Tarafenacin(SVT-40776) is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over M2 receptor.IC50 value: 0.19 nM (Ki) [1]Target: M3 muscarinic receptorin vitro: SVT-40776 is highly selective for M(3) over M(2) receptors (Ki = 0.19 nmol.L(-1) for M(3) receptor affinity). SVT-40776 was the most potent in inhibiting carbachol-induced bladder contractions of the anti-cholinergic agents tested, without affecting atrial contractions over the same range of concentrations. SVT-40776 exhibited the highest urinary versus cardiac selectivity (199-fold) [1]. SVT-40776 has a much higher binding affinity (K(d) = 0.4 nM) to M5 mAChR than that of solifenacin (K(d) = 31 nM) with the same reeptor. The calculated binding free energy change (-2.3 ± 0.3 kcal/mol) from solifenacin to SVT-40776 is in good agreement with the experimentally derived binding free energy change (-2.58 kcal/mol), suggesting that our modeled M5 mAChR structure and its complexes with the antagonists are reliable [2].in vivo: In the guinea pig in vivo model, SVT-40776 inhibited 25% of spontaneous bladder contractions at a very low dose (6.97 microg.kg(-1) i.v), without affecting arterial blood pressure [1].

Clinical Trial

NCT00507169

Salvat

Overactive Bladder (OAB)

September 2006

Phase 2

NCT01458197

Kwang Dong Pharmaceutical co., ltd.

Overactive Bladder

September 2011

Phase 2

View MoreCollapse

References

[1].Salcedo C, et al. In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol. 2009 Mar;156(5):807-17.

[2].Huang X, et al. Microscopic binding of M5 muscarinic acetylcholine receptor with antagonists by homology modeling, molecular docking, and molecular dynamics simulation. J Phys Chem B. 2012 Jan 12;116(1):532-41.